Relmada Therapeutics updates corporate presentation, no financial data disclosed

RELMADA THERAPEUTICS, INC.

Filed 8-K on April 19, 2023, to announce an updated corporate presentation.
Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders' filed as Exhibit 99.1.
No specific financial or operational milestones provided in the filing or exhibit text.
CEO Sergio Traversa signed the filing; presentation may contain pipeline or strategy updates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.